Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/29673
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOng, Wee Loon-
dc.contributor.authorFinn, Norah-
dc.contributor.authorTe Marvelde, Luc-
dc.contributor.authorHornby, Colin-
dc.contributor.authorMilne, Roger L-
dc.contributor.authorHanna, Gerard G-
dc.contributor.authorPitson, Graham-
dc.contributor.authorElsaleh, Hany-
dc.contributor.authorMillar, Jeremy L-
dc.contributor.authorForoudi, Farshad-
dc.date2022-
dc.date.accessioned2022-04-05T04:55:43Z-
dc.date.available2022-04-05T04:55:43Z-
dc.date.issued2022-03-31-
dc.identifier.citationJournal of Medical Imaging and Radiation Oncology 2022; 66(6): 830-839en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/29673-
dc.description.abstractTo evaluate the proportion of cancer patients who received radiation therapy (RT) within 12 months of cancer diagnosis (RTU12) and identify factors associated with RTU12. This is a population-based cohort of individuals with incident cancer, diagnosed between 2013 and 2017 in Victoria. Data linkages were performed between the Victorian Cancer Registry and Victorian Radiotherapy Minimum Dataset. The primary outcome was the proportion of patients who had RTU12. For the three most common cancers (i.e., prostate, breast and lung cancer), the time trend in RTU12 and factors associated with RTU12 were evaluated. The overall RTU12 in our study cohort was 26-20% radical RT and 6% palliative RT. Of the 21,735 men with prostate cancer, RTU12 was 17%, with no significant change over time (P-trend = 0.53). In multivariate analyses, increasing age and lower socioeconomic status were independently associated with higher RTU12 for prostate cancer. Of the 20,883 women with breast cancer, RTU12 was 64%, which increased from 62% in 2013 to 65% in 2017 (P-trend < 0.05). In multivariate analyses, age, socioeconomic status and area of residency were independently associated with RTU12 for breast cancer. Of the 13,093 patients with lung cancer, RTU12 was 42%, with no significant change over time (P-trend = 0.16). In multivariate analyses, younger age, male and lower socioeconomic status were independently associated with higher RTU12. In this large population-based state-wide cohort of cancer patients, only 1 in 4 had RT within 12 months of diagnosis. There were marked sociodemographic disparities in RTU12 for prostate, breast and lung cancer patients.en_US
dc.language.isoeng-
dc.subjectRadiation oncologyen_US
dc.subjectRadiotherapy utilizationen_US
dc.subjecthealth servicesen_US
dc.titleDisparities in radiation therapy utilization for cancer patients in Victoria.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Medical Imaging and Radiation Oncologyen_US
dc.identifier.affiliationCentral Clinical School, Monash University, Melbourne, Victoria, Australia..en_US
dc.identifier.affiliationDepartment of Health, State Government of Victoria, Melbourne, Victoria, Australia..en_US
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia..en_US
dc.identifier.affiliationCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia..en_US
dc.identifier.affiliationCenter for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia..en_US
dc.identifier.affiliationPrecision Medicine, School of Clinical Sciences, Monash Health, Monash University, Melbourne, Victoria, Australia..en_US
dc.identifier.affiliationDepartment of Cancer Services, Barwon Health, Geelong, Victoria, Australia..en_US
dc.identifier.affiliationAlfred Health Radiation Oncology Services, Melbourne, Victoria, Australia..en_US
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen_US
dc.identifier.affiliationDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia..en_US
dc.identifier.affiliationDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia..en_US
dc.identifier.affiliationSchool of Clinical Medicine, University of Cambridge, Cambridge, Victoria, UK..en_US
dc.identifier.affiliationVictorian Cancer Registry, Cancer Council Victoria, Melbourne, Victoria, Australia..en_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35357080/en_US
dc.identifier.doi10.1111/1754-9485.13407en_US
dc.type.contentTexten_US
dc.identifier.orcidhttps://orcid.org/0000-0001-6657-7193en_US
dc.identifier.orcidhttps://orcid.org/0000-0003-1003-5138en_US
dc.identifier.orcidhttps://orcid.org/0000-0001-8202-8602en_US
dc.identifier.orcidhttps://orcid.org/0000-0001-8387-0965en_US
dc.identifier.pubmedid35357080-
local.name.researcherForoudi, Farshad
item.languageiso639-1en-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptRadiation Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptRadiation Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on May 13, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.